Monday, September 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Pfizer Stock: Morgan Stanley Raises Target Amid Strong Earnings

Felix Baarz by Felix Baarz
August 6, 2025
in Stocks
0
Pfizer Stock
0
SHARES
43
VIEWS
Share on FacebookShare on Twitter

Pfizer’s stock received a boost as Morgan Stanley raised its price target from $32 to $33, reflecting optimism after the pharmaceutical giant reported better-than-expected Q2 results. Adjusted earnings surged 20% year-over-year to $9.6 billion, while revenue grew modestly to $28.4 billion. The company outperformed analyst estimates with Q2 earnings of $0.78 per share, 37% above projections, and revenue of $14.7 billion versus $13.47 billion expected. Management also raised its full-year adjusted EPS guidance to $2.90–$3.10, citing cost-cutting measures and strong performance from drugs like Eliquis and Xeljanz.

Regulatory Risks Loom Despite Growth

While Pfizer’s fundamentals remain strong, regulatory challenges cast a shadow. Potential U.S. tariffs of up to 250% on drug imports and government-mandated price cuts threaten profitability. The company has factored these risks into its 2025 outlook, but investor sentiment remains mixed. Shares rose 5% post-announcement, trading at $24.50, significantly outpacing the S&P 500. Analysts note the stock’s recovery from pandemic lows but caution that regulatory decisions could dictate its future trajectory.

Ad

Pfizer Stock: Buy or Sell?! New Pfizer Analysis from September 21 delivers the answer:

The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 21.

Pfizer: Buy or sell? Read more here...

Tags: Pfizer
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Uber Stock

Uber Stock: Strong Earnings Met With Market Skepticism

LifeMD Stock

LifeMD Stock: Plunge Amidst Earnings Shock and Growth Concerns

AMD Stock

AMD Stock: Mixed Results Amid China Export Woes

Recommended

Beyond Meat Stock

Beyond Meat Shares Surge in Meme-Stock Frenzy

11 months ago
iShares Global Clean Energy ETF Stock

The Hidden Concentration Risk in Clean Energy Investing

11 months ago
Solana Stock

Solana ETF Approval Looms as Regulatory Deadline Approaches

12 months ago
Macom Stock

M/A-COM Technology Shares Enter Expected Consolidation Phase

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Tokenization’s Green Light: Crypto Rallies Where Congress Stalled

5% Money Forces AI’s Believers to Show Their Math

Software Sends AI’s First Real Invoice as Yields Break 5%

Rheinmetall’s Order Book Pushes Past €80 Billion as New Shell Deal Lands

AI’s Warning Lights Flash as Crypto Steals the Spotlight

Oracle’s Backlog Defies the Bond Market While Crypto Bends

Trending

Morgan Stanley Stock
Newsletter

AI’s Next Bottleneck Isn’t Chips. It’s Cybersecurity.

by Stephanie Dugan
September 21, 2026
0

Dear readers, Yesterday we wrote about a market forced to separate cash machines from cash burners now...

Amazon Stock

Five Percent Yields Separate Cash Machines From Cash Burners

September 19, 2026
Coinbase Stock

Real Assets, Real Cash Flows: Wall Street’s Post-Hike Rotation

September 18, 2026
Coinbase Stock

Tokenization’s Green Light: Crypto Rallies Where Congress Stalled

September 17, 2026
Nvidia Stock

5% Money Forces AI’s Believers to Show Their Math

September 16, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • AI’s Next Bottleneck Isn’t Chips. It’s Cybersecurity.
  • Five Percent Yields Separate Cash Machines From Cash Burners
  • Real Assets, Real Cash Flows: Wall Street’s Post-Hike Rotation

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com